Treatment of epilepsy: with special reference to developing countries

Area of Science:

• Neurology
• Public Health
• Pharmacology

Background:

• Epilepsy is a prevalent chronic neurological disorder, posing a significant health challenge, particularly in developing nations.
• There is a notable scarcity of trained health personnel in clinical neurosciences in these regions.
• Accurate epidemiological data on epilepsy prevalence in developing countries is lacking, though it may exceed Caucasian rates.

Purpose of the Study:

• To address the diagnostic and treatment challenges of epilepsy in developing countries.
• To propose simplified pharmacotherapy strategies using readily available and economical anticonvulsant drugs.
• To identify solutions for improving epilepsy management, including healthcare integration and public education.

Main Methods:

• Review of current epilepsy management practices and challenges in developing countries.
• Analysis of essential anticonvulsant drugs for efficacy, availability, and cost-effectiveness.
• Discussion of potential strategies for improving diagnosis, treatment, and patient support.

Main Results:

• Essential drugs for common epilepsy types include phenobarbitone, phenytoin, carbamazepine, ethosuximide, and diazepam.
• Specific drug recommendations are provided for grand mal, focal, minor (generalised) epilepsies, and status epilepticus.
• Challenges include lack of diagnostic facilities, drug shortages, high patient non-adherence, and social stigma.

Conclusions:

• Simplified pharmacotherapy with available drugs can manage most epilepsy cases.
• Integrating epilepsy care into basic health systems is crucial.
• Health education, training of personnel, and research into new anticonvulsants are vital for progress.